Click for best price
Neoantigen Cancer Vaccine Market Size, Share 2023
It is through the use of tumor cell-associated antigens to awaken the body's immune system against cancer.
This report aims to provide a comprehensive presentation of the global market for Neoantigen Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neoantigen Cancer Vaccine. This report contains market size and forecasts of Neoantigen Cancer Vaccine in global, including the following market information:
Global Neoantigen Cancer Vaccine Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Neoantigen Cancer Vaccine market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Personalized Vaccine Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Neoantigen Cancer Vaccine include Roche, Medimmune, Merck, Advaxis, Agenus, Genocea, Gritstone Oncology, Neon Therapeutics and Nouscom, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Neoantigen Cancer Vaccine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neoantigen Cancer Vaccine Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Neoantigen Cancer Vaccine Market Segment Percentages, by Type, 2022 (%)
Personalized Vaccine
Off-the-shelf Neovaccines
Global Neoantigen Cancer Vaccine Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Neoantigen Cancer Vaccine Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Others
Global Neoantigen Cancer Vaccine Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Neoantigen Cancer Vaccine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neoantigen Cancer Vaccine revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Neoantigen Cancer Vaccine revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Medimmune
Merck
Advaxis
Agenus
Genocea
Gritstone Oncology
Neon Therapeutics
Nouscom
OSE Immunotherapeutics
Medigene
Vaccibody
Brightpath Biotherapeutics
Geneos Therapeutics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neoantigen Cancer Vaccine, market overview.
Chapter 2: Global Neoantigen Cancer Vaccine market size in revenue.
Chapter 3: Detailed analysis of Neoantigen Cancer Vaccine company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neoantigen Cancer Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Neoantigen Cancer Vaccine Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
61 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Neoantigen Cancer Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neoantigen Cancer Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neoantigen Cancer Vaccine Overall Market Size
2.1 Global Neoantigen Cancer Vaccine Market Size: 2022 VS 2030
2.2 Global Neoantigen Cancer Vaccine Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Neoantigen Cancer Vaccine Players in Global Market
3.2 Top Global Neoantigen Cancer Vaccine Companies Ranked by Revenue
3.3 Global Neoantigen Cancer Vaccine Revenue by Companies
3.4 Top 3 and Top 5 Neoantigen Cancer Vaccine Companies in Global Market, by Revenue in 2022
3.5 Global Companies Neoantigen Cancer Vaccine Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neoantigen Cancer Vaccine Players in Global Market
3.6.1 List of Global Tier 1 Neoantigen Cancer Vaccine Companies
3.6.2 List of Global Tier 2 and Tier 3 Neoantigen Cancer Vaccine Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Neoantigen Cancer Vaccine Market Size Markets, 2022 & 2030
4.1.2 Personalized Vaccine
4.1.3 Off-the-shelf Neovaccines
4.2 By Type - Global Neoantigen Cancer Vaccine Revenue & Forecasts
4.2.1 By Type - Global Neoantigen Cancer Vaccine Revenue, 2018-2023
4.2.2 By Type - Global Neoantigen Cancer Vaccine Revenue, 2024-2030
4.2.3 By Type - Global Neoantigen Cancer Vaccine Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Neoantigen Cancer Vaccine Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application - Global Neoantigen Cancer Vaccine Revenue & Forecasts
5.2.1 By Application - Global Neoantigen Cancer Vaccine Revenue, 2018-2023
5.2.2 By Application - Global Neoantigen Cancer Vaccine Revenue, 2024-2030
5.2.3 By Application - Global Neoantigen Cancer Vaccine Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Neoantigen Cancer Vaccine Market Size, 2022 & 2030
6.2 By Region - Global Neoantigen Cancer Vaccine Revenue & Forecasts
6.2.1 By Region - Global Neoantigen Cancer Vaccine Revenue, 2018-2023
6.2.2 By Region - Global Neoantigen Cancer Vaccine Revenue, 2024-2030
6.2.3 By Region - Global Neoantigen Cancer Vaccine Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Neoantigen Cancer Vaccine Revenue, 2018-2030
6.3.2 US Neoantigen Cancer Vaccine Market Size, 2018-2030
6.3.3 Canada Neoantigen Cancer Vaccine Market Size, 2018-2030
6.3.4 Mexico Neoantigen Cancer Vaccine Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Neoantigen Cancer Vaccine Revenue, 2018-2030
6.4.2 Germany Neoantigen Cancer Vaccine Market Size, 2018-2030
6.4.3 France Neoantigen Cancer Vaccine Market Size, 2018-2030
6.4.4 U.K. Neoantigen Cancer Vaccine Market Size, 2018-2030
6.4.5 Italy Neoantigen Cancer Vaccine Market Size, 2018-2030
6.4.6 Russia Neoantigen Cancer Vaccine Market Size, 2018-2030
6.4.7 Nordic Countries Neoantigen Cancer Vaccine Market Size, 2018-2030
6.4.8 Benelux Neoantigen Cancer Vaccine Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Neoantigen Cancer Vaccine Revenue, 2018-2030
6.5.2 China Neoantigen Cancer Vaccine Market Size, 2018-2030
6.5.3 Japan Neoantigen Cancer Vaccine Market Size, 2018-2030
6.5.4 South Korea Neoantigen Cancer Vaccine Market Size, 2018-2030
6.5.5 Southeast Asia Neoantigen Cancer Vaccine Market Size, 2018-2030
6.5.6 India Neoantigen Cancer Vaccine Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Neoantigen Cancer Vaccine Revenue, 2018-2030
6.6.2 Brazil Neoantigen Cancer Vaccine Market Size, 2018-2030
6.6.3 Argentina Neoantigen Cancer Vaccine Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Neoantigen Cancer Vaccine Revenue, 2018-2030
6.7.2 Turkey Neoantigen Cancer Vaccine Market Size, 2018-2030
6.7.3 Israel Neoantigen Cancer Vaccine Market Size, 2018-2030
6.7.4 Saudi Arabia Neoantigen Cancer Vaccine Market Size, 2018-2030
6.7.5 UAE Neoantigen Cancer Vaccine Market Size, 2018-2030
7 Neoantigen Cancer Vaccine Companies Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Neoantigen Cancer Vaccine Major Product Offerings
7.1.4 Roche Neoantigen Cancer Vaccine Revenue in Global Market (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Medimmune
7.2.1 Medimmune Company Summary
7.2.2 Medimmune Business Overview
7.2.3 Medimmune Neoantigen Cancer Vaccine Major Product Offerings
7.2.4 Medimmune Neoantigen Cancer Vaccine Revenue in Global Market (2018-2023)
7.2.5 Medimmune Key News & Latest Developments
7.3 Merck
7.3.1 Merck Company Summary
7.3.2 Merck Business Overview
7.3.3 Merck Neoantigen Cancer Vaccine Major Product Offerings
7.3.4 Merck Neoantigen Cancer Vaccine Revenue in Global Market (2018-2023)
7.3.5 Merck Key News & Latest Developments
7.4 Advaxis
7.4.1 Advaxis Company Summary
7.4.2 Advaxis Business Overview
7.4.3 Advaxis Neoantigen Cancer Vaccine Major Product Offerings
7.4.4 Advaxis Neoantigen Cancer Vaccine Revenue in Global Market (2018-2023)
7.4.5 Advaxis Key News & Latest Developments
7.5 Agenus
7.5.1 Agenus Company Summary
7.5.2 Agenus Business Overview
7.5.3 Agenus Neoantigen Cancer Vaccine Major Product Offerings
7.5.4 Agenus Neoantigen Cancer Vaccine Revenue in Global Market (2018-2023)
7.5.5 Agenus Key News & Latest Developments
7.6 Genocea
7.6.1 Genocea Company Summary
7.6.2 Genocea Business Overview
7.6.3 Genocea Neoantigen Cancer Vaccine Major Product Offerings
7.6.4 Genocea Neoantigen Cancer Vaccine Revenue in Global Market (2018-2023)
7.6.5 Genocea Key News & Latest Developments
7.7 Gritstone Oncology
7.7.1 Gritstone Oncology Company Summary
7.7.2 Gritstone Oncology Business Overview
7.7.3 Gritstone Oncology Neoantigen Cancer Vaccine Major Product Offerings
7.7.4 Gritstone Oncology Neoantigen Cancer Vaccine Revenue in Global Market (2018-2023)
7.7.5 Gritstone Oncology Key News & Latest Developments
7.8 Neon Therapeutics
7.8.1 Neon Therapeutics Company Summary
7.8.2 Neon Therapeutics Business Overview
7.8.3 Neon Therapeutics Neoantigen Cancer Vaccine Major Product Offerings
7.8.4 Neon Therapeutics Neoantigen Cancer Vaccine Revenue in Global Market (2018-2023)
7.8.5 Neon Therapeutics Key News & Latest Developments
7.9 Nouscom
7.9.1 Nouscom Company Summary
7.9.2 Nouscom Business Overview
7.9.3 Nouscom Neoantigen Cancer Vaccine Major Product Offerings
7.9.4 Nouscom Neoantigen Cancer Vaccine Revenue in Global Market (2018-2023)
7.9.5 Nouscom Key News & Latest Developments
7.10 OSE Immunotherapeutics
7.10.1 OSE Immunotherapeutics Company Summary
7.10.2 OSE Immunotherapeutics Business Overview
7.10.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Major Product Offerings
7.10.4 OSE Immunotherapeutics Neoantigen Cancer Vaccine Revenue in Global Market (2018-2023)
7.10.5 OSE Immunotherapeutics Key News & Latest Developments
7.11 Medigene
7.11.1 Medigene Company Summary
7.11.2 Medigene Business Overview
7.11.3 Medigene Neoantigen Cancer Vaccine Major Product Offerings
7.11.4 Medigene Neoantigen Cancer Vaccine Revenue in Global Market (2018-2023)
7.11.5 Medigene Key News & Latest Developments
7.12 Vaccibody
7.12.1 Vaccibody Company Summary
7.12.2 Vaccibody Business Overview
7.12.3 Vaccibody Neoantigen Cancer Vaccine Major Product Offerings
7.12.4 Vaccibody Neoantigen Cancer Vaccine Revenue in Global Market (2018-2023)
7.12.5 Vaccibody Key News & Latest Developments
7.13 Brightpath Biotherapeutics
7.13.1 Brightpath Biotherapeutics Company Summary
7.13.2 Brightpath Biotherapeutics Business Overview
7.13.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Major Product Offerings
7.13.4 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Revenue in Global Market (2018-2023)
7.13.5 Brightpath Biotherapeutics Key News & Latest Developments
7.14 Geneos Therapeutics
7.14.1 Geneos Therapeutics Company Summary
7.14.2 Geneos Therapeutics Business Overview
7.14.3 Geneos Therapeutics Neoantigen Cancer Vaccine Major Product Offerings
7.14.4 Geneos Therapeutics Neoantigen Cancer Vaccine Revenue in Global Market (2018-2023)
7.14.5 Geneos Therapeutics Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Neoantigen Cancer Vaccine Market Opportunities & Trends in Global Market
Table 2. Neoantigen Cancer Vaccine Market Drivers in Global Market
Table 3. Neoantigen Cancer Vaccine Market Restraints in Global Market
Table 4. Key Players of Neoantigen Cancer Vaccine in Global Market
Table 5. Top Neoantigen Cancer Vaccine Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Neoantigen Cancer Vaccine Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Neoantigen Cancer Vaccine Revenue Share by Companies, 2018-2023
Table 8. Global Companies Neoantigen Cancer Vaccine Product Type
Table 9. List of Global Tier 1 Neoantigen Cancer Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neoantigen Cancer Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Neoantigen Cancer Vaccine Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Neoantigen Cancer Vaccine Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Neoantigen Cancer Vaccine Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Neoantigen Cancer Vaccine Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Neoantigen Cancer Vaccine Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Neoantigen Cancer Vaccine Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2024-2030
Table 30. Roche Company Summary
Table 31. Roche Neoantigen Cancer Vaccine Product Offerings
Table 32. Roche Neoantigen Cancer Vaccine Revenue (US$, Mn) & (2018-2023)
Table 33. Roche Key News & Latest Developments
Table 34. Medimmune Company Summary
Table 35. Medimmune Neoantigen Cancer Vaccine Product Offerings
Table 36. Medimmune Neoantigen Cancer Vaccine Revenue (US$, Mn) & (2018-2023)
Table 37. Medimmune Key News & Latest Developments
Table 38. Merck Company Summary
Table 39. Merck Neoantigen Cancer Vaccine Product Offerings
Table 40. Merck Neoantigen Cancer Vaccine Revenue (US$, Mn) & (2018-2023)
Table 41. Merck Key News & Latest Developments
Table 42. Advaxis Company Summary
Table 43. Advaxis Neoantigen Cancer Vaccine Product Offerings
Table 44. Advaxis Neoantigen Cancer Vaccine Revenue (US$, Mn) & (2018-2023)
Table 45. Advaxis Key News & Latest Developments
Table 46. Agenus Company Summary
Table 47. Agenus Neoantigen Cancer Vaccine Product Offerings
Table 48. Agenus Neoantigen Cancer Vaccine Revenue (US$, Mn) & (2018-2023)
Table 49. Agenus Key News & Latest Developments
Table 50. Genocea Company Summary
Table 51. Genocea Neoantigen Cancer Vaccine Product Offerings
Table 52. Genocea Neoantigen Cancer Vaccine Revenue (US$, Mn) & (2018-2023)
Table 53. Genocea Key News & Latest Developments
Table 54. Gritstone Oncology Company Summary
Table 55. Gritstone Oncology Neoantigen Cancer Vaccine Product Offerings
Table 56. Gritstone Oncology Neoantigen Cancer Vaccine Revenue (US$, Mn) & (2018-2023)
Table 57. Gritstone Oncology Key News & Latest Developments
Table 58. Neon Therapeutics Company Summary
Table 59. Neon Therapeutics Neoantigen Cancer Vaccine Product Offerings
Table 60. Neon Therapeutics Neoantigen Cancer Vaccine Revenue (US$, Mn) & (2018-2023)
Table 61. Neon Therapeutics Key News & Latest Developments
Table 62. Nouscom Company Summary
Table 63. Nouscom Neoantigen Cancer Vaccine Product Offerings
Table 64. Nouscom Neoantigen Cancer Vaccine Revenue (US$, Mn) & (2018-2023)
Table 65. Nouscom Key News & Latest Developments
Table 66. OSE Immunotherapeutics Company Summary
Table 67. OSE Immunotherapeutics Neoantigen Cancer Vaccine Product Offerings
Table 68. OSE Immunotherapeutics Neoantigen Cancer Vaccine Revenue (US$, Mn) & (2018-2023)
Table 69. OSE Immunotherapeutics Key News & Latest Developments
Table 70. Medigene Company Summary
Table 71. Medigene Neoantigen Cancer Vaccine Product Offerings
Table 72. Medigene Neoantigen Cancer Vaccine Revenue (US$, Mn) & (2018-2023)
Table 73. Medigene Key News & Latest Developments
Table 74. Vaccibody Company Summary
Table 75. Vaccibody Neoantigen Cancer Vaccine Product Offerings
Table 76. Vaccibody Neoantigen Cancer Vaccine Revenue (US$, Mn) & (2018-2023)
Table 77. Vaccibody Key News & Latest Developments
Table 78. Brightpath Biotherapeutics Company Summary
Table 79. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Product Offerings
Table 80. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Revenue (US$, Mn) & (2018-2023)
Table 81. Brightpath Biotherapeutics Key News & Latest Developments
Table 82. Geneos Therapeutics Company Summary
Table 83. Geneos Therapeutics Neoantigen Cancer Vaccine Product Offerings
Table 84. Geneos Therapeutics Neoantigen Cancer Vaccine Revenue (US$, Mn) & (2018-2023)
Table 85. Geneos Therapeutics Key News & Latest Developments
List of Figures
Figure 1. Neoantigen Cancer Vaccine Segment by Type in 2022
Figure 2. Neoantigen Cancer Vaccine Segment by Application in 2022
Figure 3. Global Neoantigen Cancer Vaccine Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Neoantigen Cancer Vaccine Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Neoantigen Cancer Vaccine Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Neoantigen Cancer Vaccine Revenue in 2022
Figure 8. By Type - Global Neoantigen Cancer Vaccine Revenue Market Share, 2018-2030
Figure 9. By Application - Global Neoantigen Cancer Vaccine Revenue Market Share, 2018-2030
Figure 10. By Type - Global Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Neoantigen Cancer Vaccine Revenue Market Share, 2018-2030
Figure 12. By Application - Global Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Neoantigen Cancer Vaccine Revenue Market Share, 2018-2030
Figure 14. By Region - Global Neoantigen Cancer Vaccine Revenue Market Share, 2018-2030
Figure 15. By Country - North America Neoantigen Cancer Vaccine Revenue Market Share, 2018-2030
Figure 16. US Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Neoantigen Cancer Vaccine Revenue Market Share, 2018-2030
Figure 20. Germany Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 21. France Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Neoantigen Cancer Vaccine Revenue Market Share, 2018-2030
Figure 28. China Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 32. India Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Neoantigen Cancer Vaccine Revenue Market Share, 2018-2030
Figure 34. Brazil Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Neoantigen Cancer Vaccine Revenue Market Share, 2018-2030
Figure 37. Turkey Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2018-2030
Figure 41. Roche Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Medimmune Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Merck Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Advaxis Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Agenus Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Genocea Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Gritstone Oncology Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Neon Therapeutics Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Nouscom Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. OSE Immunotherapeutics Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Medigene Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Vaccibody Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Geneos Therapeutics Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
